StockMacro
Company, fund or insider

Help

Menu

Guardian Pharmacy Services

$46.94 +22% in 6 monthsMarket cap $3.0B

GRDN on XNYS, Retail, Guardian Pharmacy Services, Inc., job postings

Measures activity, not value. Not investment advice.

Shares rose 70% in a year while quarterly revenue slipped 1.7% to $371.1M.

  • GoodNet income rose 86% to $74.8M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.

Industry
Retail-drug stores and proprietary stores (Retail)
Employees
3,600
Website
guardianpharmacy.com
Listed
NYSE, US
Last results
5 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $371.1M, net income $18.7M.
Quarter to 30 Sep 2023: revenue $262.7M, net income -$7.0MQuarter to 30 Sep 2023: revenue $262.7M, net income -$7.0MQuarter to 31 Mar 2024: revenue $275.4M, net income $7.1MQuarter to 31 Mar 2024: revenue $275.4M, net income $7.1MQuarter to 30 Jun 2024: revenue $300.0M, net income $15.8MQuarter to 30 Jun 2024: revenue $300.0M, net income $15.8MQuarter to 30 Sep 2024: revenue $314.4M, net income -$122.0MQuarter to 30 Sep 2024: revenue $314.4M, net income -$122.0MQuarter to 31 Dec 2024: revenue $338.6M, net income $11.9MQuarter to 31 Dec 2024: revenue $338.6M, net income $11.9MQuarter to 31 Mar 2025: revenue $329.3M, net income $9.4MQuarter to 31 Mar 2025: revenue $329.3M, net income $9.4MQuarter to 30 Jun 2025: revenue $344.3M, net income $9.0MQuarter to 30 Jun 2025: revenue $344.3M, net income $9.0MQuarter to 30 Sep 2025: revenue $377.4M, net income $9.8MQuarter to 30 Sep 2025: revenue $377.4M, net income $9.8MQuarter to 31 Dec 2025: revenue $397.6M, net income $20.9MQuarter to 31 Dec 2025: revenue $397.6M, net income $20.9MQuarter to 31 Mar 2026: revenue $336.6M, net income $13.3MQuarter to 31 Mar 2026: revenue $336.6M, net income $13.3MQuarter to 30 Jun 2026: revenue $351.8M, net income $21.9MQuarter to 30 Jun 2026: revenue $351.8M, net income $21.9MQuarter to 30 Sep 2026: revenue $371.1M, net income $18.7MQuarter to 30 Sep 2026: revenue $371.1M, net income $18.7M
30 Sep 2023RevenueNet incomeNet losstallest bar $397.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$371.1M$18.7M
30 Jun 2026$351.8M$21.9M
31 Mar 2026$336.6M$13.3M
31 Dec 2025$397.6M$20.9M
30 Sep 2025$377.4M$9.8M
30 Jun 2025$344.3M$9.0M
31 Mar 2025$329.3M$9.4M
31 Dec 2024$338.6M$11.9M
30 Sep 2024$314.4M-$122.0M
30 Jun 2024$300.0M$15.8M
31 Mar 2024$275.4M$7.1M
30 Sep 2023$262.7M-$7.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.5B $1.4B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +4.9% +4.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $74.8M $40.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 22.4% 19.7% 37.9%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 6.5% 4.2% 4.1%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 5.1% 2.9% 2.7%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 31.5% 12.0%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $119.7M $36.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.45
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 39.8 19.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.0 0.58
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 0.89
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 10.6 2.3

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Guardian Pharmacy ServicesGRDN (this company) $3.0B39.82.0+4.9%5.1%
Shake ShackSHAK $2.9B66.61.8+17%2.7%
Group 1 AutomotiveGPI $3.0B8.00.14-3.4%1.7%
Advance Auto PartsAAP $2.7B––––
PatternPTRN $3.3B27.81.0+42%3.6%
Bobs Discount FurnitureBOBS $2.6B––––

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-1.7%

$371.1M vs $377.4M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$251K

bought $0, sold $251K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+4.3%

195 13F filers vs 187

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

2.2M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.6

2.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-7.5%

2.4M shares sold short in the report before, 2.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

62%

62% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 59%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

12

12 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

12×

12 articles in the last 7 days; its usual week has 1.

Price $46.94 on 20 Nov 2026, +70% over 12 months (12-month range $27.03 to $50.33)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $313.4M in the last 12 months (the 12 months before: -$254.6M).
Revenue per quarter. Revenue $371.1M in the latest quarter, -1.7% on a year earlier.
Capital spending per quarter. Capital spending $495K in the latest quarter, -78% on a year earlier.
Institutional holders (13F filers). 195 13F filers reported holding it in the latest 13F quarter, +81% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
22 Jun 20268-K and other filingsDirector or officer change
22 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 May 20258-K and other filingsRegistered new securities for sale (S-1)
28 Mar 20258-K and other filingsDirector or officer change
11 Feb 20258-K and other filingsDirector or officer change
11 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Oct 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 650K)
30 Sep 20248-K and other filingsDirector or officer change
30 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
22 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
3 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Oct 2024: $650K published
Month from 1 Nov 2024: $149K published
Month from 1 May 2025: -$228.7M published
Month from 1 Oct 2025: -$25.9M published
Month from 1 Dec 2025: $100K published
Month from 1 Mar 2026: -$313.2M published
Month from 1 Nov 2026: -$251K published
Revenue per quarter
Quarter ended 30 Sep 2023: $262.7M; public on 13 Nov 2024
Quarter ended 31 Mar 2024: $275.4M; public on 13 May 2025
Quarter ended 30 Jun 2024: $300.0M; public on 12 Aug 2025
Quarter ended 30 Sep 2024: $314.4M, +20% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $338.6M; public on 12 Mar 2026
Quarter ended 31 Mar 2025: $329.3M, +20% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $344.3M, +15% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $377.4M, +20% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $397.6M, +17% on a year earlier; public on 12 Mar 2026
Quarter ended 31 Mar 2026: $336.6M, +2.2% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $351.8M, +2.2% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $371.1M, -1.7% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2024: $2.2M; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $2.2M; public on 12 Mar 2026
Quarter ended 30 Sep 2025: $4.0M, +80% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $495K, -78% on a year earlier; public on 12 Mar 2026
Institutional holders (13F filers)
30 Sep 2024 report: 48; public on 14 Nov 2024
31 Dec 2024 report: 66; public on 14 Feb 2025
31 Mar 2025 report: 72; public on 15 May 2025
30 Jun 2025 report: 100; public on 14 Aug 2025
30 Sep 2025 report: 108; public on 14 Nov 2025
31 Dec 2025 report: 126; public on 17 Feb 2026
31 Mar 2026 report: 168; public on 15 May 2026
30 Jun 2026 report: 187; public on 14 Aug 2026
30 Sep 2026 report: 195; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is operating income, fiscal year at $72.7M (31 Dec 2025), 216% below its normal quarter of -$62.9M.
  • Insider net buying (open market): Insiders sold a net $313.4M in the last 12 months (the 12 months before: -$254.6M).
  • Revenue per quarter: Revenue $371.1M in the latest quarter, -1.7% on a year earlier.
  • Capital spending per quarter: Capital spending $495K in the latest quarter, -78% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 26 insider trades

Last 90 days: 1 sale, $251K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026David Norman MartinSee RemarksSell5,000$50.25$251KForm 4
24 Mar 2026William E BindleyDirector, 10% ownerSell3,570,677$29.68$106.0MForm 4
24 Mar 2026Bindley Capital Partners I, LLC10% ownerSell3,570,677$29.68$106.0MForm 4
24 Mar 2026Kendall ForbesSee RemarksSell346,672$29.68$10.3MForm 4
24 Mar 2026John AckermanDirectorSell1,103,364$29.68$32.7MForm 4
24 Mar 2026David K MorrisSee RemarksSell187,855$29.68$5.6MForm 4
24 Mar 2026Fred BurkeSee RemarksSell671,432$29.68$19.9MForm 4
24 Mar 2026Pharmacy Investors, LLCMember of 10% owner groupSell827,636$29.68$24.6MForm 4

195 institutions reported shares at the end of Q3 2026; 28 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)3.3M$134.7M+62K+1.9%
BlackRock, Inc.2.4M$98.6M+843K+53%
Wellington Management Group LLP2.2M$90.6M+492K+28%
Vanguard Capital Management LLC1.4M$59.0M+67K+4.9%
Woodline Partners LP1.3M$53.3MNo change
T. Rowe Price Investment Management, Inc.1.2M+51K+4.6%
Loomis Sayles & Co L P1.1M$43.7M+201K+23%
Geode Capital Management, LLC950K$38.7M+303K+47%
Franklin Templeton Inc862K$36.3M-104K-11%
Valiant Capital Management, L.P.803K$32.8M-383K-32%

Company events

All 13 company events

In 12 months: 2 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
22 Jun 2026Director or officer change8-K
28 May 2026Signed a major agreementSame filing: took on new debt8-K
23 Mar 2026Signed a major agreement8-K
20 May 2025Signed a major agreement8-K
20 May 2025Registered new securities for sale (S-1)S-1
28 Mar 2025Director or officer change8-K
11 Feb 2025Director or officer change8-K
20 Dec 2024Signed a major agreementSame filing: took on new debt8-K

The 5 newest of 77 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 22 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 22 Jun 2026Filings record

    Director or officer change

  3. 6 Dec 2025Insiders record

    COSLER STEVEN D (director) bought 3,370 shares of GRDN ($99,786) (dated 5 Dec 2025)

  4. 20 May 2025Filings record

    Registered new securities for sale (S-1)

  5. 28 Mar 2025Filings record

    Director or officer change

  6. 11 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 11 Feb 2025Filings record

    Director or officer change

  8. 21 Nov 2024Insiders record

    COSLER STEVEN D (director) bought 7,000 shares of GRDN ($148,540) (dated 20 Nov 2024)

  9. 2 Oct 2024Insiders change

    had 3 insiders buy $650K of its shares on the open market within 30 days (3 filings).

    Who bought: Cosler Steven D, Salentine Thomas J Jr, Lewis Randall J.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $650K
    Window
    2 Sep 2024 to 2 Oct 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  10. 2 Oct 2024Insiders record

    Patchett Mary Sue (director) bought 3,571 shares of GRDN [same transaction as an earlier filing] (dated 1 Oct 2024)

  11. 2 Oct 2024Insiders record

    LEWIS RANDALL J (director) bought 3,571 shares of GRDN ($49,994) (dated 1 Oct 2024)

  12. 2 Oct 2024Insiders record

    Salentine Thomas J Jr (director) bought 35,714 shares of GRDN ($499,996) (dated 1 Oct 2024)

  13. 2 Oct 2024Insiders record

    COSLER STEVEN D (director) bought 7,142 shares of GRDN ($99,988) (dated 1 Oct 2024)

  14. 30 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 30 Sep 2024Filings record

    Director or officer change

  16. 16 Sep 2024Filings record

    Registered new securities for sale (S-1)

  17. 22 Aug 2024Filings record

    Registered new securities for sale (S-1)

  18. 3 Oct 2023Filings record

    Registered new securities for sale (S-1)

Not listed: 48 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001802255
Ticker
GRDN
Domain
guardianpharmacy.com
Hq location
GA|ATLANTA|30339 (1 unverified)
Name
Guardian Pharmacy, LLC, Guardian Pharmacy of Arizona, LLC, Guardian Pharmacy of Atlanta, LLC, Guardian Pharmacy of Birmingham, LLC and 51 more
  • SEC Form 13F institutional holdings81 data points30 Sep 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)36 records3 Oct 2023 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)151 data points31 Dec 2022 to 30 Sep 2026
  • SEC Form 4 insider transactions26 records, 28 data points1 Oct 2024 to 19 Nov 2026
  • FINRA short interest (twice monthly)152 data points30 Sep 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1082 data points26 Sep 2024 to 20 Nov 2026